Hexamethylmelamine as Consolidation Treatment for Patients with Advanced Epithelial Ovarian Cancer in Complete Response after First-Line Chemotherapy.
10.3346/jkms.2009.24.4.679
- Author:
Yong Soon KWON
1
;
Joo Hyun NAM
;
Dae Yeon KIM
;
Dae Shik SUH
;
Jong Hyeok KIM
;
Yong Man KIM
;
Young Tak KIM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea. jhnam@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Altretamine;
Consolidation Therapy;
Advanced Epithelial Ovarian Cancer
- MeSH:
Altretamine/*therapeutic use;
Antineoplastic Agents, Alkylating/*therapeutic use;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use;
Disease-Free Survival;
Female;
Humans;
Middle Aged;
Neoplasm Staging;
Neoplasms, Glandular and Epithelial/*drug therapy/mortality;
Ovarian Neoplasms/*drug therapy/mortality;
Retrospective Studies
- From:Journal of Korean Medical Science
2009;24(4):679-683
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete response from advanced ovarian cancer following front-line platinum-based therapy were retrospectively analyzed. The patients treated with HMM were compared to the patients of matched counterpart without consolidation therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment. For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235). No treatment-related adverse events were reported during the follow-up period. Although this study failed to show the significant survival benefit of consolidation therapy with HMM in patients with advanced EOC, we consider that our study can contribute data to investigate the effectiveness of consolidation therapy in epithelial ovarian cancer.
